The Cell & Gene Therapy Manufacturing Services Market is valued at USD 8.5 billion in 2025 and is projected to grow at a CAGR of 15.5% to reach USD 31.1 billion by 2034.
The cell & gene therapy manufacturing services market is a rapidly expanding segment within the biopharmaceutical industry, providing specialized production capabilities for cutting-edge treatments. These services encompass the manufacturing of cell-based therapies, gene-modified cells, and viral vectors used to treat complex diseases such as cancer, genetic disorders, and rare conditions. With a growing pipeline of advanced therapies in clinical development, demand for high-quality, scalable, and compliant manufacturing services is on the rise.
Manufacturing cell and gene therapies involves complex processes that require stringent quality controls, advanced bioprocessing technologies, and state-of-the-art facilities. Contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) play a vital role in this market by providing the expertise, infrastructure, and regulatory know-how needed to meet the unique challenges of these therapies. These third-party providers help streamline production timelines, ensure compliance with global standards, and reduce the financial burden on biotech firms and pharmaceutical companies.
Geographically, North America leads the market, driven by a strong presence of biopharmaceutical companies, robust R&D investment, and supportive regulatory frameworks. Europe follows closely, with significant government funding and initiatives to foster cell and gene therapy innovation. The Asia-Pacific region is also experiencing rapid growth, fueled by rising healthcare investments, increasing clinical trials, and the establishment of local manufacturing facilities. This global demand underscores the importance of the cell & gene therapy manufacturing services market in advancing the next generation of medical treatments.
<
Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behavior are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.
Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.
This product will be delivered within 1-3 business days.
The cell & gene therapy manufacturing services market is a rapidly expanding segment within the biopharmaceutical industry, providing specialized production capabilities for cutting-edge treatments. These services encompass the manufacturing of cell-based therapies, gene-modified cells, and viral vectors used to treat complex diseases such as cancer, genetic disorders, and rare conditions. With a growing pipeline of advanced therapies in clinical development, demand for high-quality, scalable, and compliant manufacturing services is on the rise.
Manufacturing cell and gene therapies involves complex processes that require stringent quality controls, advanced bioprocessing technologies, and state-of-the-art facilities. Contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) play a vital role in this market by providing the expertise, infrastructure, and regulatory know-how needed to meet the unique challenges of these therapies. These third-party providers help streamline production timelines, ensure compliance with global standards, and reduce the financial burden on biotech firms and pharmaceutical companies.
Geographically, North America leads the market, driven by a strong presence of biopharmaceutical companies, robust R&D investment, and supportive regulatory frameworks. Europe follows closely, with significant government funding and initiatives to foster cell and gene therapy innovation. The Asia-Pacific region is also experiencing rapid growth, fueled by rising healthcare investments, increasing clinical trials, and the establishment of local manufacturing facilities. This global demand underscores the importance of the cell & gene therapy manufacturing services market in advancing the next generation of medical treatments.
<
Key Insights: Cell & Gene Therapy Manufacturing Services Market
- Growing reliance on CDMOs for end-to-end solutions, including process development, scale-up, and regulatory support.
- Increased adoption of automation and digital technologies to enhance production efficiency, consistency, and traceability.
- Expansion of single-use technologies and modular manufacturing platforms to reduce contamination risks and improve scalability.
- Advancements in viral vector production methods, including suspension-based systems, to meet the growing demand for gene therapies.
- Greater focus on decentralized manufacturing models, enabling more localized and flexible production of personalized therapies.
- Expanding pipeline of cell and gene therapies in clinical development, driving demand for scalable manufacturing solutions.
- Increased regulatory approvals and growing commercial availability of advanced therapies, boosting market confidence and investment.
- Technological advancements in bioprocessing and quality control, enabling more efficient and cost-effective production.
- Growing partnerships and collaborations between biotech companies and CDMOs, fostering innovation and reducing time-to-market.
- High manufacturing costs and the complexity of scaling up production without compromising quality.
- Shortage of skilled personnel and specialized facilities, leading to bottlenecks in manufacturing capacity.
- Regulatory hurdles and varying compliance requirements across regions, increasing complexity for global players.
Cell & Gene Therapy Manufacturing Services Market Segmentation
By Type
- Gene Therapy
- Cell Therapy
By Indication
- Central Nervous System Disorders
- Ophthalmology Diseases
- Cardiovascular Diseases
- Infectious Diseases
- Orthopedic Diseases
- Oncology Diseases
By Application
- Commercial Manufacturing
- Clinical Manufacturing
By End-user
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Other End-Users
Key Companies Analysed
- Lonza Group AG
- Catalent, Inc.
- Thermo Fisher Scientific Inc. (Patheon)
- WuXi AppTec Co., Ltd.
- Sartorius AG
- Charles River Laboratories
- Samsung Biologics
- Fujifilm Diosynth Biotechnologies
- Oxford Biomedica plc
- AGC Biologics
Cell & Gene Therapy Manufacturing Services Market Analytics
The report employs rigorous tools, including Porter’s Five Forces, value chain mapping, and scenario-based modeling, to assess supply-demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behavior are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.
Cell & Gene Therapy Manufacturing Services Market Competitive Intelligence
The competitive landscape is mapped through proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analyzed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.
Countries Covered
- North America - Cell & Gene Therapy Manufacturing Services market data and outlook to 2034
- United States
- Canada
- Mexico
- Europe - Cell & Gene Therapy Manufacturing Services market data and outlook to 2034
- Germany
- United Kingdom
- France
- Italy
- Spain
- BeNeLux
- Russia
- Sweden
- Asia-Pacific - Cell & Gene Therapy Manufacturing Services market data and outlook to 2034
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Malaysia
- Vietnam
- Middle East and Africa - Cell & Gene Therapy Manufacturing Services market data and outlook to 2034
- Saudi Arabia
- South Africa
- Iran
- UAE
- Egypt
- South and Central America - Cell & Gene Therapy Manufacturing Services market data and outlook to 2034
- Brazil
- Argentina
- Chile
- Peru
Research Methodology
This study combines primary inputs from industry experts across the Cell & Gene Therapy Manufacturing Services value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.Key Questions Addressed
- What is the current and forecast market size of the Cell & Gene Therapy Manufacturing Services industry at global, regional, and country levels?
- Which types, applications, and technologies present the highest growth potential?
- How are supply chains adapting to geopolitical and economic shocks?
- What role do policy frameworks, trade flows, and sustainability targets play in shaping demand?
- Who are the leading players, and how are their strategies evolving in the face of global uncertainty?
- Which regional “hotspots” and customer segments will outpace the market, and what go-to-market and partnership models best support entry and expansion?
- Where are the most investable opportunities - across technology roadmaps, sustainability-linked innovation, and M&A - and what is the best segment to invest over the next 3-5 years?
Your Key Takeaways from the Cell & Gene Therapy Manufacturing Services Market Report
- Global Cell & Gene Therapy Manufacturing Services market size and growth projections (CAGR), 2024-2034
- Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Cell & Gene Therapy Manufacturing Services trade, costs, and supply chains
- Cell & Gene Therapy Manufacturing Services market size, share, and outlook across 5 regions and 27 countries, 2023-2034
- Cell & Gene Therapy Manufacturing Services market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034
- Short- and long-term Cell & Gene Therapy Manufacturing Services market trends, drivers, restraints, and opportunities
- Porter’s Five Forces analysis, technological developments, and Cell & Gene Therapy Manufacturing Services supply chain analysis
- Cell & Gene Therapy Manufacturing Services trade analysis, Cell & Gene Therapy Manufacturing Services market price analysis, and Cell & Gene Therapy Manufacturing Services supply/demand dynamics
- Profiles of 5 leading companies - overview, key strategies, financials, and products
- Latest Cell & Gene Therapy Manufacturing Services market news and developments
Additional Support
With the purchase of this report, you will receive:- An updated PDF report and an MS Excel data workbook containing all market tables and figures for easy analysis.
- 7-day post-sale analyst support for clarifications and in-scope supplementary data, ensuring the deliverable aligns precisely with your requirements.
- Complimentary report update to incorporate the latest available data and the impact of recent market developments.
This product will be delivered within 1-3 business days.
Table of Contents
1. Table of Contents
2. Global Cell & Gene Therapy Manufacturing Services Market Summary, 2025
3. Cell & Gene Therapy Manufacturing Services Market Insights, 2024-2034
4. Cell & Gene Therapy Manufacturing Services Market Analytics
5. Global Cell & Gene Therapy Manufacturing Services Market Statistics - Industry Revenue, Market Share, Growth Trends and Forecast by segments, to 2034
6. Asia Pacific Cell & Gene Therapy Manufacturing Services Industry Statistics - Market Size, Share, Competition and Outlook
7. Europe Cell & Gene Therapy Manufacturing Services Market Data, Penetration, and Business Prospects to 2034
8. North America Cell & Gene Therapy Manufacturing Services Market Size, Growth Trends, and Future Prospects to 2034
9. South and Central America Cell & Gene Therapy Manufacturing Services Market Drivers, Challenges, and Future Prospects
10. Middle East Africa Cell & Gene Therapy Manufacturing Services Market Outlook and Growth Prospects
11. Cell & Gene Therapy Manufacturing Services Market Structure and Competitive Landscape
12 Appendix
Companies Mentioned
- Lonza Group AG
- Catalent Inc.
- Thermo Fisher Scientific Inc. (Patheon)
- WuXi AppTec Co. Ltd.
- Sartorius AG
- Charles River Laboratories
- Samsung Biologics
- Fujifilm Diosynth Biotechnologies
- Oxford Biomedica PLC
- AGC Biologics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | October 2025 |
| Forecast Period | 2025 - 2034 |
| Estimated Market Value ( USD | $ 8.5 Billion |
| Forecasted Market Value ( USD | $ 31.1 Billion |
| Compound Annual Growth Rate | 15.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
